Cervical Cancer Prevention

  • Katherine LaVigne
  • Mario M. LeitaoJrEmail author


Cervical cancer is the most common gynecologic malignancy worldwide, accounting for about 530,000 new cases each year. Most of these cases (85%) occur in the developing world and worldwide it is the third most common malignancy and the fourth leading cause of cancer death in women (Jemal A et al. CA Cancer J Clin 61:69–90, 2011; Jemal A et al. J Natl Cancer Inst 2013). By contrast, in the United States of America (USA) cervical cancer has decreased dramatically since the introduction of cytologic screening (Pap smear), and is now a relatively infrequent neoplasm, especially among well-screened majority populations with access to healthcare services. In the USA, an individual woman’s lifetime risk of developing cervical cancer is estimated to be 1 in 147. In 2017, it is estimated that there were approximately 12,820 new cases of cervical cancer and 4210 deaths in the USA (Siegel RL et al. CA Cancer J Clin 67:7–30, 2017).


Cervical cancer screening Cervical cancer prevention HPV HPV vaccine HPV testing Cervical intraepithelial neoplasia 


  1. Abma JC et al (2004) Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat 23(24):1–48Google Scholar
  2. Agarwal SS, Sehgal A et al (1993) Role of male behavior in cervical carcinogenesis among women with one lifetime sexual partner. Cancer 72(5):1666–1669PubMedCrossRefGoogle Scholar
  3. Ahn WS, Yoo J et al (2003) Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 12(5):383–390PubMedCrossRefGoogle Scholar
  4. Alberts DS, Barakat RR et al (2004) Prevention of gynecologic malignancies. In: Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas G (eds) Gynecologic cancer: controversies in management. Elsevier Ltd, PhiladelphiaGoogle Scholar
  5. Al-saleh W, Delvenne P et al (1995) Inverse modulation of intraepithelial Langerhans’ cells and stromal macrophage/dendrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. Virchows Arch 427(1):41–48PubMedCrossRefGoogle Scholar
  6. Alvarez RD, Conner MG et al (2003) The efficacy of 9-cis-retinoic acid (alitretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomark Prev 12(2):114–119Google Scholar
  7. Anttila A, Pukkala E et al (1999) Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer 83(1):59–65PubMedCrossRefGoogle Scholar
  8. Ashing-Giwa KT, Gonzalez P, Lim JW, Chung C, Paz B, Somlo G, Wakabayashi MT (2010) Diagnostic and therapeutic delays among a multiethnic sample of breast and cervical cancer survivors. Cancer 116(13):3195–3204. Scholar
  9. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ (2005) A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 58:1096–1100PubMedPubMedCentralCrossRefGoogle Scholar
  10. Barker B, Garcia F et al (2001) The correlation between colposcopically directed cervical biopsy and loop electrosurgical excision procedure pathology and the effect of time on that agreement. Gynecol Oncol 82(1):22–26PubMedCrossRefGoogle Scholar
  11. Barr E (2005) Gardasil HPV vaccine. Centers for Disease Control and Prevention, National Immunization Program meeting of the Advisory Committee on Immunization Practices, February 10–11, AtlantaGoogle Scholar
  12. Barr E (2006) Garadasil HPV vaccine. Centers for Disease Control and Prevention, National Immunization Program meeting of the Advisory Committee on Immunization Practices, February 21–22, AtlantaGoogle Scholar
  13. Bell MC, Crowley-Nowick P et al (2000) Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78(2):123–129PubMedCrossRefGoogle Scholar
  14. Brinton LA, Reeves WC et al (1989) Parity as a risk factor for cervical cancer. Am J Epidemiol 130(3):486–496PubMedCrossRefGoogle Scholar
  15. Brun JL, Dalstein V et al (2011) Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204(2):169.e1–169.e8CrossRefGoogle Scholar
  16. Buckley JD, Harris RW et al (1981) Case–control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. Lancet 2(8254):1010–1015PubMedCrossRefGoogle Scholar
  17. Butterworth CE Jr, Hatch KD, Soong SJ, Cole P, Tamura T, Sauberlich HE, Baker V (1992) Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol 166(3):803–809PubMedCrossRefGoogle Scholar
  18. Castanon A, Tristram A, Mesher D, Powell N, Beer H, Ashman S, Sasieni P (2012) Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Br J Cancer 106(1):45–52PubMedCrossRefGoogle Scholar
  19. Castellsague X, Bosch FX et al (2002) Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346(15):1105–1112PubMedCrossRefGoogle Scholar
  20. CDC, Centers for Disease Control and Prevention (1999) (2012) Youth risk behavior surveillance—United States, 2011. MMWR 61(SS-4):1–162Google Scholar
  21. Cheng AL, Hsu CH et al (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B):2895–2900PubMedGoogle Scholar
  22. Childers JM, Chu J, Voigt LF, Feigl P, Tamimi HK, Franklin EW, Meyskens FL Jr (1995) Chemoprevention of cervical cancer with folic acid: a phase III southwest oncology group intergroup study. Cancer Epidemiol Biomark Prev 4(2):155–159Google Scholar
  23. Choo KB, Pan CC et al (1987) Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 161(1):259–261PubMedCrossRefGoogle Scholar
  24. Clerici M, Merola M et al (1997) Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 89(3):245–250PubMedCrossRefGoogle Scholar
  25. Clerici M, Shearer GM et al (1998) Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst 90(4):261–263PubMedCrossRefGoogle Scholar
  26. Cohen CR, Brown J, Moscicki AB, Bukusi EA, Paull JR, Price CF, Shiboski S (2011) A phase I randomized placebo controlled trial of the safety of 3% SPL7013 gel (VivaGel(R)) in healthy young women administered twice daily for 14 days. PLoS One 6(1):e16258PubMedPubMedCentralCrossRefGoogle Scholar
  27. Coker A, Bond S (1999) Persistent oncogenic HPV and risk of SIL progression and LSIL maintenance. In: 18th international human papillomavirus conference, CharlestonGoogle Scholar
  28. Coleman N, Birley HD et al (1994) Immunological events in regressing genital warts. Am J Clin Pathol 102(6):768–774PubMedCrossRefGoogle Scholar
  29. de Vet HC, Sturmans F et al (1994) The role of cigarette smoking in the etiology of cervical dysplasia. Epidemiology 5(6):631–633PubMedCrossRefGoogle Scholar
  30. Deacon JM, Evans CD et al (2000) Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case–control study nested within the Manchester cohort. Br J Cancer 83(11):1565–1572PubMedPubMedCentralCrossRefGoogle Scholar
  31. Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA (2010) Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol 116(3):464–467PubMedCrossRefGoogle Scholar
  32. Denk C, Butz K et al (2001) p53 mutations are rare events in recurrent cervical cancer. J Mol Med 79(5–6):283–288PubMedCrossRefGoogle Scholar
  33. Ding Z, Green AG et al (2002) Retinoic acid inhibits telomerase activity and downregulates expression but does not affect splicing of hTERT: correlation with cell growth rate inhibition in an in vitro cervical carcinogenesis/multidrug-resistance model. Exp Cell Res 272(2):185–191PubMedCrossRefGoogle Scholar
  34. Fahey MT, Irwig L et al (1995) Meta-analysis of Pap test accuracy. Am J Epidemiol 141(7):680–689PubMedCrossRefGoogle Scholar
  35. Farley JH, Truong V, Goo E, Uyehara C, Belnap C, Larsen WI (2006) A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor celecoxib in the treatment of cervical dysplasia. Gynecol Oncol 103(2):425–430PubMedCrossRefGoogle Scholar
  36. Fast Stats (2013) An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed 14 Jan 2013
  37. Follen M, Atkinson EN et al (2001) A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 7(11):3356–3365PubMedGoogle Scholar
  38. Follen M, Meyskens FL Jr et al (2003) Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer 98(Suppl 9):2044–2051PubMedCrossRefGoogle Scholar
  39. Franco EL (1996) Epidemiology of anogenital warts and cancer. Obstet Gynecol Clin N Am 23(3):597–623Google Scholar
  40. Frazer IH, Quinn M et al (2004) Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23(2):172–181PubMedCrossRefGoogle Scholar
  41. Future II Study Group (2007a) Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 196(10):1438–1446CrossRefGoogle Scholar
  42. Future II Study Group (2007b) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927CrossRefGoogle Scholar
  43. Garcia F, Mendez de Galaz E et al (2003) Factors that affect the quality of cytologic cervical cancer screening along the Mexico-United States border. Am J Obstet Gynecol 189(2):467–472PubMedCrossRefGoogle Scholar
  44. Garcia F, Petry KU et al (2004) ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 103(2):317–326PubMedCrossRefGoogle Scholar
  45. García-Hernández E, González-Sánchez JL et al (2006) Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13(6):592–597PubMedCrossRefGoogle Scholar
  46. Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943PubMedCrossRefGoogle Scholar
  47. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR et al (2016) Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 63(4):519–527PubMedPubMedCentralCrossRefGoogle Scholar
  48. Giannini SL, Al-Saleh W et al (1998) Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 113(2):183–189PubMedPubMedCentralCrossRefGoogle Scholar
  49. Gierisch JM, Coeytaux RR, Urrutia RP et al (2013) Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomark Prev 22:1931CrossRefGoogle Scholar
  50. Graham V, Surwit ES, Weiner S, Meyskens FL Jr (1986) Phase II trial of beta-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. West J Med 145(2):192–195PubMedPubMedCentralGoogle Scholar
  51. Grubbs CJ, Steele VE et al (1995) Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15(3):709–716PubMedGoogle Scholar
  52. Harper DM et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765PubMedCrossRefGoogle Scholar
  53. Harper DM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518):1247–1255PubMedCrossRefGoogle Scholar
  54. Hefler LA, Grimm C, Speiser P, Sliutz G, Reinthaller A (2006) The cyclooxygenase-2 inhibitor rofecoxib (vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. Eur J Obstet Gynecol Reprod Biol 125(2):251–254PubMedCrossRefGoogle Scholar
  55. Hefler L, Grimm C, Tempfer C, Reinthaller A (2010) Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. Anticancer Res 30(4):1257–1261PubMedGoogle Scholar
  56. Hernandez B, Goodman M (1999) Association of HPV viral load and risk of cervical squamous intraepithelial neoplasia (SIL) among multi-ethnic women in Hawaii. In: 18th international human papillomavirus conference, CharlestonGoogle Scholar
  57. Hildesheim A, Herrero R, Wacholder S et al (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7):743–753PubMedCrossRefGoogle Scholar
  58. Ho GY, Burk RD et al (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87(18):1365–1371PubMedCrossRefGoogle Scholar
  59. Ho GY, Bierman R et al (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338(7):423–428PubMedCrossRefGoogle Scholar
  60. Howe SL, Delfino RJ et al (1998) The risk of invasive cervical cancer among Hispanics: evidence for targeted preventive interventions. Prev Med 27(5. Pt 1):674–680PubMedCrossRefGoogle Scholar
  61. Howell EA, Chen YT et al (1999) Differences in cervical cancer mortality among black and white women. Obstet Gynecol 94(4):509–515PubMedGoogle Scholar
  62. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, et al. (2012) SEER cancer statistics review, 1975–2009 (Vintage 2009 Populations). Based on November 2011 SEER data submission. National Cancer Institute, Bethesda
  63. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH (2015) Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Obstet Gynecol 125(2):330–337PubMedCrossRefGoogle Scholar
  64. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609Google Scholar
  65. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Edwards BK (2013) Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. Scholar
  66. Jones BA, Novis DA (2000) Follow-up of abnormal gynecologic cytology: a college of American pathologists Q-probes study of 16,132 cases from 306 laboratories. Arch Pathol Lab Med 124(5):665–671PubMedGoogle Scholar
  67. Jones DL, Alani RM et al (1997) The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 11(16):2101–2111PubMedPubMedCentralCrossRefGoogle Scholar
  68. Joura EA, Giuliano AR, Iversen OE et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:711PubMedCrossRefGoogle Scholar
  69. Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Berman ML (2001) A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomark Prev 10(10):1029–1035Google Scholar
  70. Kim JH, Bae SN, Lee CW, Song MJ, Lee SJ, Yoon JH, Park JS (2011) A pilot study to investigate the treatment of cervical human papillomavirus infection with zinc-citrate compound (CIZAR(R)). Gynecol Oncol 122(2):303–306PubMedCrossRefGoogle Scholar
  71. Konya J, Dillner J (2001) Immunity to oncogenic human papillomaviruses. Adv Cancer Res 82:205–238PubMedCrossRefGoogle Scholar
  72. Koutsky LA, Holmes KK et al (1992) A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327(18):1272–1278PubMedCrossRefGoogle Scholar
  73. Koutsky LA, Ault KA et al (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347(21):1645–1651PubMedCrossRefGoogle Scholar
  74. Leyden WA, Manos MM, Geiger AM et al (2005) Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 97:675–683PubMedCrossRefGoogle Scholar
  75. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128:927–935PubMedCrossRefGoogle Scholar
  76. Londesborough P, Ho L et al (1996) Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 69(5):364–368PubMedCrossRefGoogle Scholar
  77. Mackerras D, Irwig L, Simpson JM, Weisberg E, Cardona M, Webster F, Ghersi D (1999) Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 79(9–10):1448–1453PubMedPubMedCentralCrossRefGoogle Scholar
  78. Maiman M (1998) Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr (23):43–49CrossRefGoogle Scholar
  79. Manetta A, Schubbert T, Chapman J, Schell MJ, Peng YM, Liao SY, Meyskens FJ Jr (1996) Beta-carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomark Prev 5(11):929–932Google Scholar
  80. Manhart L, Holmes KK, Koutsky LA, Wood TR, Kenney DL, Feng Q, Kiviat N (2006) Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 33(8):502–508PubMedCrossRefGoogle Scholar
  81. Mao C et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107:18–27PubMedCrossRefGoogle Scholar
  82. Markowitz LE, Dunne EF, Saraiya M et al (2014) Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 63:1PubMedGoogle Scholar
  83. Martin-Hirsch P, Paraskevaidis E et al (2000) Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2:CD001318Google Scholar
  84. McCann MF, Irwin DE et al (1992) Nicotine and cotinine in the cervical mucus of smokers, passive smokers, and nonsmokers. Cancer Epidemiol Biomark Prev 1(2):125–129Google Scholar
  85. Meijer CJ, Nobbenhuis MA et al (1999) Human papillomavirus and cervical lesions in a prospective study of 353 women with abnormal cytology. In: 18th international human papillomavirus conference, CharlestonGoogle Scholar
  86. Meisels A, Morin C et al (1983) Human papillomavirus (HPV) venereal infections and gynecologic cancer. Pathol Annu 18(Pt 2):277–293PubMedGoogle Scholar
  87. Meyskens FL Jr, Graham V et al (1983) A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst 71(5):921–925PubMedGoogle Scholar
  88. Meyskens FL Jr, Surwit E et al (1994) Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 86(7):539–543PubMedCrossRefGoogle Scholar
  89. Miller NB (2007) Gardasil™: quadrivalent human papillomavirus 6, 11, 16, 18 L1 VLP Vaccine. FDA review of the Gardasil license application. Accessed 3 April 2008
  90. Mitchell JB, McCormack LA (1997) Time trends in late-stage diagnosis of cervical cancer. Differences by race/ethnicity and income. Med Care 35(12):1220–1224PubMedCrossRefGoogle Scholar
  91. Mitchell MF, Tortolero-Luna G et al (1998a) A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 92(5):737–744PubMedCrossRefGoogle Scholar
  92. Mitchell MF, Tortolero-Luna G et al (1998b) Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4(2):303–310PubMedGoogle Scholar
  93. Montz FJ (2000) Management of high-grade cervical intraepithelial neoplasia and low-grade squamous intraepithelial lesion and potential complications. Clin Obstet Gynecol 43(2):394–409PubMedCrossRefGoogle Scholar
  94. Morris M, Tortolero-Luna G et al (1996) Cervical intraepithelial neoplasia and cervical cancer. Obstet Gynecol Clin N Am 23(2):347–410Google Scholar
  95. Moscicki AB, Shiboski S et al (1998) The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 132(2):277–284PubMedCrossRefGoogle Scholar
  96. Moscicki AB, Hills N, Shiboski S et al (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285:2995–3002PubMedCrossRefGoogle Scholar
  97. Muderspach L, Wilczynski S et al (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6(9):3406–3416PubMedGoogle Scholar
  98. Munoz N, Franceschi S et al (2002) Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case–control study. Lancet 359(9312):1093–1101 [see comments]CrossRefGoogle Scholar
  99. Munoz N, Bosch FX et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527PubMedCrossRefGoogle Scholar
  100. Nagelkerke N, Bernsen R, Sgaier SK, Jha P (2006) Body mass index, sexual behaviour, and sexually transmitted infections: an analysis using the NHANES 1999–2000 data. BMC Public Health 6:199PubMedPubMedCentralCrossRefGoogle Scholar
  101. Napoles-Springer A, Perez-Stable EJ et al (1996) Risk factors for invasive cervical cancer in Latino women. J Med Syst 20(5):277–293PubMedCrossRefGoogle Scholar
  102. Nastala CL, Edington HD et al (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153(4):1697–1706PubMedGoogle Scholar
  103. Ostor AG (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12(2):186–192PubMedCrossRefGoogle Scholar
  104. Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580):2161–2170PubMedCrossRefGoogle Scholar
  105. Palefsky JM, Holly EA (1995) Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomark Prev 4(4):415–428Google Scholar
  106. Parkin DM, Vizcaino AP et al (1994) Cancer patterns and risk factors in the African population of southwestern Zimbabwe, 1963–1977. Cancer Epidemiol Biomark Prev 3(7):537–547Google Scholar
  107. Prokopczyk B, Cox JE et al (1997) Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 89(12):868–873PubMedCrossRefGoogle Scholar
  108. Richardson H, Kelsall G et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomark Prev 12(6):485–490Google Scholar
  109. Robinson CL, Romero JR, Kempe A et al (2017) Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2017. MMWR Morb Mortal Wkly Rep 66:134PubMedPubMedCentralCrossRefGoogle Scholar
  110. Roman LD, Wilczynski S et al (2007) A phase II study of hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 106(3):558–566PubMedCrossRefGoogle Scholar
  111. Romney SL, Dwyer A, Slagle S, Duttagupta C, Palan PR, Basu J, Kadish A (1985) Chemoprevention of cervix cancer: phase I–II: a feasibility study involving the topical vaginal administration of retinyl acetate gel. Gynecol Oncol 20(1):109–119PubMedCrossRefGoogle Scholar
  112. Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, Burk RD (1997) Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 65(3):483–492PubMedCrossRefGoogle Scholar
  113. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M et al (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:524–532PubMedCrossRefGoogle Scholar
  114. Ruffin MT, Bailey JM, Normolle DP, Michael CW, Bieniasz ME, Kmak DC, Brenner DE (2004) Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomark Prev 13(12):2148–2152Google Scholar
  115. Salani R, Khanna N, Frimer M, Bristow RE, Chen LM (2017) An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146:3–10PubMedCrossRefGoogle Scholar
  116. Samson S-LA, Bentley JR et al (2005) The effect of LEEP electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol 105(2):325–332PubMedCrossRefGoogle Scholar
  117. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, Waldman J (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 16(3):175–204. Scholar
  118. Sawaya GF, Washington AE (1999) Cervical cancer screening: which techniques should be used and why? Clin Obstet Gynecol 42:922–938PubMedCrossRefGoogle Scholar
  119. Scarinci IC, Garcia FAR, Kobetz E, Partridge EE, Brandt HM, Bell MC, Castle PE (2010) Cervical cancer prevention. Cancer 116(11):2531–2542PubMedPubMedCentralGoogle Scholar
  120. Scheffner M, Huibregtse JM et al (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75(3):495–505PubMedCrossRefGoogle Scholar
  121. Schiffman MH, Bauer HM et al (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85(12):958–964PubMedCrossRefGoogle Scholar
  122. Schiffman MH, Kjaer SK (2003) Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31:14–19CrossRefGoogle Scholar
  123. Schwartz PE, Hadjimichael O, Lowell DM et al (1996) Rapidly progressive cervical cancer: the Connecticut experience. Am J Obstet Gynecol 175:1105–1109PubMedCrossRefGoogle Scholar
  124. Sheets EE, Urban RG et al (2003) Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188(4):916–926PubMedCrossRefGoogle Scholar
  125. Sherman ME, Schiffman M et al (2002) Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 94(2):102–107PubMedCrossRefGoogle Scholar
  126. Shirodkar S, Ewen M et al (1992) The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68(1):157–166PubMedCrossRefGoogle Scholar
  127. Shukla S, Bharti AC et al (2009) Elimination of high-risk human papillomavirus type HPV16 infection by ‘praneem’ polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol 135(12):1701–1709PubMedCrossRefGoogle Scholar
  128. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. Scholar
  129. Simon P, Buxant F et al (2003) Cervical response to vaccination against HPV16 E7 in case of severe dysplasia. Eur J Obstet Gynecol Reprod Biol 109(2):219–223PubMedCrossRefGoogle Scholar
  130. Sizemore N, Choo CK et al (1998) Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells. Exp Cell Res 244(1):349–356PubMedCrossRefGoogle Scholar
  131. Solares AM, Baladron I et al (2011) Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human, proof-of-concept trial. ISRN Obstet Gynecol 2011:1–9CrossRefGoogle Scholar
  132. Surwit EA, Graham V et al (1982) Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 143(7):821–823PubMedCrossRefGoogle Scholar
  133. ter Harmsel B, Smedts F et al (1999) Relationship between human papillomavirus type 16 in the cervix and intraepithelial neoplasia. Obstet Gynecol 93(1):46–50CrossRefGoogle Scholar
  134. Thomas DB, Ray RM et al (1996) Prostitution, condom use, and invasive squamous cell cervical cancer in Thailand. Am J Epidemiol 143(8):779–786PubMedCrossRefGoogle Scholar
  135. Thorland EC, Myers SL et al (2000) Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res 60(21):5916–5921PubMedGoogle Scholar
  136. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics 2012. CA Cancer J Clin 65(2):87–108PubMedPubMedCentralCrossRefGoogle Scholar
  137. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Wu TC (2009) A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15(1):361–367PubMedPubMedCentralCrossRefGoogle Scholar
  138. Vaccarella S, Franceschi S, Herrero R et al (2006) Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomark Prev 15(2):326–333CrossRefGoogle Scholar
  139. van Duin M, Snijders PJ et al (2002) Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 98(4):590–595PubMedCrossRefGoogle Scholar
  140. Van Pachterbeke C, Bucella D et al (2009) Topical treatment of CIN 2+ by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 115(1):69–74PubMedCrossRefGoogle Scholar
  141. Villa LL et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278PubMedCrossRefGoogle Scholar
  142. Vlastos AT, West LA, Atkinson EN, Boiko I, Malpica A, Hong WK, Follen M (2005) Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin Cancer Res 11(1):390–396PubMedGoogle Scholar
  143. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, Giuliano A (2008) Burden of cervical cancer in the United States, 1998–2003. Cancer 113(10 Suppl):2855–2864. Scholar
  144. Wattenberg LW, Loub WD (1978) Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 38(5):1410–1413PubMedGoogle Scholar
  145. Weiner SA, Surwit EA et al (1986) A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy. Investig New Drugs 4(3):241–244CrossRefGoogle Scholar
  146. Winer RL, Lee SK, Hughes JP et al (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 57:218–226CrossRefGoogle Scholar
  147. Wright TC Jr (1994) Precancerous lesions of the cervix. In: Kurman R (ed) Blaustein’s pathology of the female genital tract. Springer, New York, pp 229–278CrossRefGoogle Scholar
  148. Wright TC Jr, Lorincz A et al (1998) Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 178(5):962–966PubMedCrossRefGoogle Scholar
  149. Wright TC, Cox JT et al (2002) 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287:2120–2129PubMedCrossRefGoogle Scholar
  150. Wright TC Jr, Cox JT et al (2003) 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 189(1):295–304PubMedCrossRefGoogle Scholar
  151. Wright TC Jr, Schiffman M et al (2004) Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103(2):304–309PubMedCrossRefGoogle Scholar
  152. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL (2014) Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. In: Gynecol OncolGoogle Scholar
  153. Yoo KY, Kang D et al (1997) Risk factors associated with uterine cervical cancer in Korea: a case- control study with special reference to sexual behavior. J Epidemiol 7(3):117–123PubMedCrossRefGoogle Scholar
  154. Zola H, Roberts-Tompson P et al (1995) Diagnostic immunopathology. Cambridge University Press, CambridgeGoogle Scholar
  155. Zunzunegui MV, King MC et al (1986) Male influences on cervical cancer risk. Am J Epidemiol 123(2):302–307PubMedCrossRefGoogle Scholar
  156. zur Hausen H (1977) Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78:1–30PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Gynecology Service, Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations